Clinical trials: Immune System Function
Low Back Pain
Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients…
- Trial name
- NCT00246155
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ipsen
Asthma
A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects
PF-03893787, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.
- Trial name
- NCT00856687
- Testing
- PF-03893787, Montelukast
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Pfizer
New-onset Type 1 Diabetes
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
The objective of this clinical trial was to assess whether ladarixin treatment is effective to improve glycemic control in newly diagnosed Type 1 Diabetes (T1D) adult patients with preserved β-cell function.
- Trial name
- NCT04899271
- Testing
- Ladarixin
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Dompé Farmaceutici S.p.A
Alzheimer Disease, Cognitive Impairment
Multi-Center Study of Sensory Stimulation to Improve Brain Function
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
- Trial name
- Overture (NCT03556280)
- Testing
- GammaSense Stimulation System (Active Settings)
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cognito Therapeutics, Inc.
Multiple Myeloma
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in…
- Trial name
- DREAMM 13 (NCT04398680)
- Testing
- Belantamab mafodotin
- Where
- 18 sites in United States, Greece and 1 more
- Sponsor
- GlaxoSmithKline
Islet Transplantation in Diabetes Mellitus Type 1
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
The objective of this clinical trial was: to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic control following intra-hepatic infusion of pancreatic islets in patients with Type 1 diabetes…
- Trial name
- REP0211 (NCT01817959)
- Testing
- Reparixin
- Where
- 9 sites in United States, Czechia and 3 more
- Volunteers
- 51 people
- Sponsor
- Dompé Farmaceutici S.p.A
Healthy, Gastrointestinal Diseases
Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune Function
Human Milk Oligosaccharides (HMOs) are the third most abundant class of nutrients in human milk. Studies investigating the effects of dietary HMOs in infants have shown various health and developmental benefits such as the…
- Trial name
- NCT06094153
- Testing
- HMO 1, HMO 2
- Where
- Singapore
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Kyowa Hakko Bio Co., Ltd.
Mitral Valve Regurgitation (Degenerative or Functional)
Edwards EVOQUE Eos MISCEND Study
Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
- Trial name
- NCT02718001
- Testing
- Edwards EVOQUE Eos Mitral Valve Replacement System
- Where
- 19 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Edwards Lifesciences
Hyperthyroidism, Graves Disease
AI-Based Wearable Monitoring (Glandy HYPER) for Antithyroid Drug Dose Adjustment in Graves' Disease
Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI).
- Conditions
- Hyperthyroidism, Graves Disease, Thyrotoxicosis
- Trial name
- NCT07857421
- Testing
- Glandy HYPER (AI-based monitoring software), Methimazole
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- THYROSCOPE INC.
Asthma
Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function
The proposed study is designed to investigate the pharmacokinetics, pharmacodynamics (as measured by serum cortisol) and safety of GW685698X in subjects with moderate hepatic impairment and in healthy subjects following a single…
- Trial name
- NCT00419237
- Testing
- GW685698X
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Mild Cognitive Impairment
Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms
CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Multiple Sclerosis, Mild Cognitive Impairment, Cancer
- Trial name
- NCT05438147
- Testing
- CT-100 DiNaMo, Care-as-Usual
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Click Therapeutics, Inc.
Rheumatoid Arthritis
Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of filgotinib and its metabolite, GS-829845, in participants with varying degrees of impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT03417778
- Testing
- Filgotinib
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Type 1 Diabetes
DIATOR-Diabetes Intervention With Atorvastatin
Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator.
- Trial name
- NCT00974740
- Testing
- Atorvastatin
- Where
- 12 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
HIV, AIDS
TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
The purpose of this study is to investigate the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) after a single dose and after repeated administration of…
- Conditions
- HIV, AIDS, Hepatic Impairment
- Trial name
- NCT00736905
- Testing
- TMC278
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Positive
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
The health of the immune system in HIV infected people is currently determined from a blood test measuring the number of cluster of differentiation 4 (CD4) T lymphocytes. These cells play a critical role in an immune response.
- Trial name
- QFM (NCT01904201)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- QIAGEN Gaithersburg, Inc
Moderate and Severe Plaque Psoriasis
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease…
- Trial name
- NCT00885196
- Testing
- AEB071
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 336 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Asthma
A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
The purpose of the study is to evaluate in subjects suffering from nocturnal asthma, the efficacy and safety of modified release Prednisone on signs and symptoms.
- Trial name
- MONA (NCT00686335)
- Testing
- Lodotra, Cortancyl
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Amgen